Company

Surge Therapeutics, Inc.

Surge Therapeutics is developing localized immunotherapy delivery to help prevent cancer recurrence after surgery.

About

Surge Therapeutics is a biotechnology company based in Massachusetts, US, founded in 2021 by Michael Goldberg. Its SURGERx platform is designed to deliver immunotherapy locally after tumor removal surgery using an injectable biodegradable hydrogel. In July 2023, the company raised USD 32 million in Series B funding led by Bioluminescence Ventures, with KdT Ventures, Piedmont Capital Investments, 8VC, Alumni Ventures, Camford Capital, Cancer Research Institute, Intuitive Ventures, Khosla Ventures, and Pitango Venture Capital participating.

2Funding rounds

9Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in